DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Notice of Meeting

AGENCY: Agency for Healthcare Research and Quality, HHS.

ACTION: Notice.

SUMMARY: In accordance with section 10 (a)(2) of the Federal Advisory Committee Act, announcement is made of an Agency for Healthcare Research and Quality (AHRQ) Special Emphasis Panel (SEP) meeting on AHRQ-HS-20-001, “Improving Management of Opioids and Opioid Use Disorder (OUD) in Older Adults (R18).”

This SEP meeting will be closed to the public.

DATES: May 29, 2020

ADDRESSES: Agency for Healthcare Research and Quality

(Virtual Review)

5600 Fishers Lane

Rockville, Maryland 20850

FOR FURTHER INFORMATION CONTACT: Anyone wishing to obtain a roster of members, agenda or minutes of the non-confidential portions of this meeting should contact:

Jenny Griffith
Acting Committee Management Officer

Office of Extramural Research, Education and Priority Populations, AHRQ

5600 Fishers Lane

Rockville, Maryland 20850

Telephone: (301)427-1557

Agenda items for this meeting are subject to change as priorities dictate.

SUPPLEMENTARY INFORMATION: A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the Agency for Healthcare Research and Quality (AHRQ), and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.

The SEP meeting referenced above will be closed to the public in accordance with the provisions set forth in 5 U.S.C. App. 2, section 10(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for the AHRQ-HS-20-001, “Improving Management of Opioids and Opioid Use Disorder (OUD) in Older Adults (R18)” is to be reviewed and discussed at this meeting. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Dated: May 1, 2020.

Virginia L. Mackay-Smith,

Associate Director.

[FR Doc. 2020-09723 Filed: 5/6/2020 8:45 am; Publication Date: 5/7/2020]